Key result
EPC capture stenting succeeds in a chronic ITP patient with only spontaneously resolving ecchymosis.
Why the study?
Coronary stenting in patients with chronic immune thrombocytopenic purpura poses a clinical challenge due to increased bleeding risk with antiplatelet therapy.
Case Report (n=1)
Endothelial progenitor cell capture stents via a transradial approach may be a feasible revascularization strategy in patients with chronic immune thrombocytopenic purpura who require antiplatelet therapy.
May support EPC capture stenting feasibility in chronic ITP; hypothesis-generating and requires prospective validation before wider use.
A patient with long-standing immune thrombocytopenic purpura (ITP) would logically contradict antiplatelet use due to increased bleeding risk during coronary stenting. Coronary stenting using an endothelial progenitor cells (EPC) capture stents (Genous™) was used to successfully revascularise our patient using a transradial approach. The only complication was extensive superficial ecchymosis on the patient's forearm from antiplatelet use, which resolved spontaneously. To the best of our knowledge, this is the first case report of EPC capture stents in a chronic ITP patient.
No takes yet. Share an insight, caveat, or question.
Hak et al. (2012) conducted a case report in Chronic immune thrombocytopenic purpura (ITP) requiring coronary stenting (n=1). Coronary stenting using an endothelial progenitor cells (EPC) capture stent (Genous™) was evaluated on Successful revascularization and complications. Coronary stenting using an endothelial progenitor cells capture stent was successfully performed in a patient with chronic ITP, with the only complication being spontaneously resolving ecchymosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: